Trial Profile
A Single Arm, Open Lable, Dose Escalation Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy of KN026 Monotherapy in Patients With HER2-positive Advanced Malignant Breast and Gastric Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Anbenitamab (Primary)
- Indications Advanced breast cancer; Gastric cancer; HER2 positive breast cancer
- Focus Adverse reactions; First in man
- Sponsors Alphamab Oncology
- 11 Mar 2024 Status changed from active, no longer recruiting to completed.
- 29 Nov 2021 Results published in the Clinical Cancer Research.
- 16 Nov 2021 Status changed from recruiting to active, no longer recruiting.